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doi:10.1Objective: The development of a tissue-engineered vascular graft with the ability to grow and remodel holds
promise for advancing cardiac surgery. In 2001, we began a human trial evaluating these grafts in patients
with single ventricle physiology. We report the late clinical and radiologic surveillance of a patient cohort that
underwent implantation of tissue-engineered vascular grafts as extracardiac cavopulmonary conduits.
Methods: Autologous bone marrow was obtained and the mononuclear cell component was collected. Mononu-
clear cells were seeded onto a biodegradable scaffold composed of polyglycolic acid and e-caprolactone/L-lactide
and implanted as extracardiac cavopulmonary conduits in patients with single ventricle physiology. Patients were
followed up by postoperative clinic visits and by telephone. Additionally, ultrasonography, angiography, com-
puted tomography, and magnetic resonance imaging were used for postoperative graft surveillance.
Results: Twenty-five grafts were implanted (median patient age, 5.5 years). There was no graft-related mortality
(mean follow-up, 5.8 years). There was no evidence of aneurysm formation, graft rupture, graft infection, or ec-
topic calcification. One patient had a partial mural thrombosis that was successfully treated with warfarin. Four
patients had graft stenosis and underwent successful percutaneous angioplasty.
Conclusion: Tissue-engineered vascular grafts can be used as conduits in patients with single ventricle physiol-
ogy. Graft stenosis is the primary mode of graft failure. Further follow-up and investigation for the mechanism of
stenosis are warranted. (J Thorac Cardiovasc Surg 2010;139:431-6)E
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Approximately 1% of all live births are affected by congen-
ital heart disease, and each year approximately 10,000 chil-
dren undergo reconstructive operations to repair complex
congenital abnormalities.1 Currently used prosthetic mate-
rials, such as polytetrafluoroethylene, lack growth potential
and are prone to thrombosis and infection. Additionally,
prosthetic materials are nonviable and do not possess the
ability to grow.
Through tissue engineering, it is feasible to construct
a vascular graft that has structural and biochemical charac-
teristics similar to those of a native vessel.2 By use of the
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The Journal of Thoracic and Cacells can be seeded onto a biodegradable scaffold, with the
scaffold providing a source of cell attachment and early
structural integrity.3 As the scaffold degrades, vascular neo-
tissue forms and a living, biocompatible conduit is created.
We4 have previously reported the satisfactory short-term
results of a human trial in which tissue-engineered vascular
grafts (TEVGs) were implanted as extracardiac total cavo-
pulmonary connections (TCPCs) in 25 patients with single
ventricle physiology. In this study, we report the long-term
clinical and radiologic surveillance of the patient cohort
that underwent implantation of TEVGs as extracardiac
TCPCs. Several imaging modalities, including angiography,
computed tomography (CT), magnetic resonance imaging
(MRI) angiography, and transthoracic ultrasonography,
were used to assess TEVG patency and morphology.MATERIAL AND METHODS
Scaffold Fabrication
A hybrid tubular scaffold composed of a woven fabric of polyglycolic
acid and e-caprolactone or L-lactide was constructed as previously de-
scribed.4 On the basis of vessel size and hemodynamics, the appropriate di-
ameter scaffold was selected (range, 12–24 mm). The scaffolds were 0.6 to
0.7 mm in thickness and 13 cm in length. The length of the scaffold was
modified by the surgical team as necessary to accommodate each patient’s
anatomy.
Cell Collection and Scaffold Preparation
As described previously,4 with the patient under general anesthesia and
before median sternotomy for the definitive operation, bone marrow (5 mL/
kg body weight) was aspirated from the anterosuperior iliac spine. The
mononuclear cell component of the marrow (2.26  1.02 3 108 cells)rdiovascular Surgery c Volume 139, Number 2 431
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CT ¼ computed tomography
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Swas collected with Histopaque-1077 (Sigma Chemical Co, St Louis, Mo)
centrifugation, and these cells were seeded onto the scaffold by manual pi-
petting. The seeded scaffold was incubated in diluted autologous plasma for
2 hours before implantation.
Surgical Implantation
In 2001, the ethics committee at TokyoWomen’sMedical University ap-
proved the implantation of TEVGs in human subjects. The following inclu-
sion criteria were used for patient screening: elective surgery, age younger
than 30 years, full understanding of the procedure by the patient or family,
and minimal extracardiac disease burden. Informed consent was obtained
from each patient, or from the parent/guardian if the patient was a minor,
before proceeding. Between September 2001 and December 2004, 25 pa-
tients underwent an extracardiac TCPC using a TEVG (Table E1). The me-
dian patient age at the time of TEVG implantation was 5.5 years (range 1–24
years). The mean patient body weight at the time of TEVG implantation was
19.5 kg (range 7.5–51.6 kg). The patients who had small grafts (patients 17
and 19) had an azygos connection. Anticoagulation therapy with warfarin
sodium and aspirin was started 2 days postoperatively and continued for
3 to 6 months. Patients were monitored radiographically with transthoracic
echocardiography, multislice CT, cineangiography, or MRI angiography.
Patients were followed up postoperatively in a multidisciplinary clinic. Ad-
ditionally, all patients were contacted by telephone to confirm their most re-
cent clinical status.RESULTS
Early Trial Results
We defined early results as clinical and radiographic
events within 30 days of patient discharge after TEVG im-
plantation. At this point, all patients were alive and free of
symptoms. Postoperative angiography, ultrasonography, or
CT demonstrated that all TEVGs were patent and there
was no evidence of stenosis, thrombosis, or aneurysmal di-
lation of the TEVG.Trial Results 1 Year After Implantation
Patients continued to be monitored with angiography, ul-
trasonography, MRI angiography, or CT (Figure E1). Partial
mural thrombosis in 1 patient was successfully treated with
warfarin anticoagulation (Figure E2). A patient with hypo-
plastic left heart syndrome died 6 months after TEVG im-
plantation of congestive heart failure resulting from severe
triscuspid regurgitation (Table 1).Most Recent Follow-up
There was no graft-related mortality during the follow-up
period (range, 4.3–7.3 years; mean, 5.8 years). All patients
underwent a catheterization-based angiographic study, CT,432 The Journal of Thoracic and Cardiovascular SurgorMRI. There was no evidence of aneurysm formation, graft
rupture, or ectopic calcification in any graft interrogated with
any imaging modality (Figure 1). Of note, 1 patient had
a hemiazygous connection, and a 12-mm diameter TEVG
was implanted; this graft was patent as demonstrated by
postoperative imaging. In addition to the patient noted above
in the 1-year analysis, 3 other patients died after TEVG im-
plantation: A patient with tricuspid atresia died of complica-
tions related to subarachnoid hemorrhage 4 years after
TEVG implantation; a second patient, with a known coro-
nary artery anomaly diagnosed on cardiac catheterization,
died suddenly 4 years postoperatively; a third patient, who
had subaortic stenosis, died suddenly 2 years after graft im-
plantation. Significantly, surveillance imaging in the months
before all 4 patient deaths (including the patient who died
during the midterm analysis) demonstrated a patent
TEVG. Six (24%) patients had asymptomatic graft narrow-
ing noted on routine surveillance imaging. Four of 6 patients
underwent successful balloon angioplasty (Figure 2), in-
cluding 1 patient who required repeat balloon angioplasty
and stent placement in the stenosed segment of the TEVG
(Table 2).
Postoperative Functional Status
Surviving subjects were contacted by telephone in Janu-
ary 2009 to determine their current functional status. All
contacted patients were attending school or work regularly.
Seventeen (81%) patients were in New York Heart Associ-
ation functional class I and 3 patients were in functional class
II. Eight patients (40%) were not receiving any daily medi-
cations (Table 3).
DISCUSSION
Inasmuch as the prosthetic material used as conduits
in surgery for congenital heart disease lacks growth poten-
tial, surgical reintervention is often necessary.5,6 Addition-
ally, synthetic grafts are at risk for thrombosis or infection.
In an effort to overcome these limitations, we have applied
tissue-engineering technology to the field of cardiac
surgery. On the basis of several initial animal experi-
ments,2,7-10 we have previously reported the successful im-
plantation of TEVGs in humans (average follow-up, 1.3
years). In an effort to better characterize graft morbidity
and mortality, we continued to monitor our surgical popu-
lation clinically and radiographically. Our mean follow-up
is now 5.8 years, and to this point no graft-related deaths
have occurred. In a patient population that often has severe
cardiovascular compromise, with a concomitantly short-
ened life expectancy, our data suggest that TEVGs are
technically feasible.
One of the chief advantages of tissue engineering is the
potential to create autologous tissue, obviating the need for
antiplatelet, anticoagulant, or immunosuppressive therapy.
In this study, anticoagulation and antiplatelet agents wereery c February 2010
TABLE 1. Patient status 1 year after TEVG implantation
Patient Age at operation (y) Graft type Graft size (cm) Patient status Graft status Graft patency Graft-related complications
1 2 PLA 16 Alive Intact Patent None
2 1 PLA 20 Alive Intact Patent None
3 7 PLA 1 8 Alive Intact Patent None
4 21 PLA 24 Alive Intact Patent None
5 4 PLA 20 Alive Intact Patent None
6 12 PLA 24 Alive Intact Patent None
7 17 PLA 24 Alive Intact Patent None
8 19 PLA 22 Alive Intact Patent None
9 3 PLA 12 Alive Intact Patent None
10 2 PLA 16 Dead Intact Patent None
11 2 PGA 16 Alive Intact Patent None
12 13 PLA 20 Alive Intact Patent None
13 2 PGA 16 Alive Intact Patent Thrombosis
14 2 PGA 18 Alive Intact Patent None
15 2 PGA 12 Alive Intact Patent None
16 2 PGA 16 Alive Intact Patent None
17 24 PGA 18 Alive Intact Patent None
18 1 PGA 16 Alive Intact Patent None
19 11 PGA 18 Alive Intact Patent None
20 2 PGA 16 Alive Intact Patent None
21 3 PGA 16 Alive Intact Patent None
22 4 PGA 18 Alive Intact Patent None
23 4 PGA 18 Alive Intact Patent None
24 13 PGA 16 Alive Intact Patent None
25 2 PGA 18 Alive Intact Patent None
TEVG, Tissue-engineered vascular graft; PLA, poly-L-lactic acid; PGA, Polyglycolic acid.




Sdiscontinued 6months postoperatively in all patients with no
evidence of graft thrombosis (96%). In the long term, 40%
of patients remained free of any daily medications, which
improves quality of life and decreases the incidence of med-
ication-related complications and comorbidities. In contrast,
in studies investigating artificial graft materials such as
Dacron or polytetrafluoroethylene, most subjects received
long-term oral anticoagulation with warfarin or antiplatelet
therapy with aspirin.11-13
The remodeling of TEVGs and the mechanisms of vascu-
lar neotissue formation remain a most compelling andFIGURE 1. TEVG angiography, 5 years after implantation (A) and 4 years aft
calcification in these TEVGs.
The Journal of Thoracic and Caintensely studied subject. In this study, surveillance imaging
revealed graft stenoses in 6 (24%) patients. This stenosis
rate was greater than in those studies investigating artificial
graft material.11-13 Graft stenosis, however, is frequently
asymptomatic, leading to significant underreporting.14
When serially imaged with MRI, all synthetic grafts have
some degree of stenosis within 6 months of implantation,
with a mean 18% reduction in diameter and a maximum re-
duction of 32%.11 These finding were confirmed in a second
study evaluating extracardiac TCPC graft morphology using
angiography.15 Graft narrowing tended to stabilize after thiser implantation (B). There was no stenosis, aneurysm formation, or ectopic
rdiovascular Surgery c Volume 139, Number 2 433
FIGURE 2. Four patients (A–D) with TEVG stenosis underwent successful balloon angioplasty. PTA, Percutaneous transluminal angioplasty.




Sinitial period, but the use of angioplasty and stenting is de-
scribed in many series.11,16 Additionally, the degree of ste-
nosis is difficult to estimate based on a variety of
variables, including the change of shape of a conduit from
a circular cross section to an oval cross section that often oc-
curs. Also, the 3-dimensional nature of vascular grafts limits
accurate size and boundary detection with 2-dimensional
modalities such as angiography.15 Finally, indications for
the therapy of asymptomatic stenosis are not standardized,434 The Journal of Thoracic and Cardiovascular Surgleading to significant variability in the use of angioplasty,
stenting, and graft replacement.
The limitations of this study must be acknowledged. Al-
though this trial represents the first use of tissue-engineered
conduits in humans, the number of study subjects was rela-
tively small and only a single institution was involved. Fur-
thermore, a standard radiologic surveillance protocol was
not adhered to. Finally, this study was not randomized
with matched controls. Currently, we are applying to theery c February 2010
TABLE 2. Patient late-term status after TEVG implantation
Patient Age at operation Graft type Graft size (cm) Patient status Graft status Graft patency Graft-related complications
1 2 PLA 16 Alive Intact Patent None
2 1 PLA 20 Alive Intact Patent None
3 7 PLA 18 Alive Intact Patent Stenosis*
4 21 PLA 24 Alive Intact Patent None
5 4 PLA 20 Alive Intact Patent None
6 12 PLA 24 Alive Intact Patent None
7 17 PLA 24 Alive Intact Patent None
8 19 PLA 22 Dead Intact Patent None
9 3 PLA 12 Alive Intact Patent Stenosis*
10 2 PLA 16 Dead Intact Patent None
11 2 PLA 20 Dead Intact Patent None
12 13 PGA 16 Alive Intact Patent Stenosis*
13 2 PGA 16 Alive Intact Patent Thrombosis
14 2 PGA 18 Alive Intact Patent None
15 2 PGA 12 Alive Intact Patent None
16 2 PGA 16 Alive Intact Patent None
17 24 PGA 18 Alive Intact Patent None
18 1 PGA 16 Alive Intact Patent Stenosis*
19 11 PGA 18 Alive Intact Patent None
20 2 PGA 16 Alive Intact Patent None
21 3 PGA 16 Alive Intact Patent None
22 4 PGA 18 Alive Intact Patent None
23 4 PGA 18 Alive Intact Patent None
24 13 PGA 16 Alive Intact Patent None
25 2 PGA 18 Dead Intact Patent None
TEVG, Tissue-engineered vascular graft; PLA, poly-L-lactic acid; PGA, Polyglycolic acid. *This patient underwent successful angioplasty.
TABLE 3. Summary of the results of TEVG telephone survey




weight (weight at surgery)
1 Yes Alive & well I Yes Yes 27 kg (11 kg)
2 Yes Alive & well I Yes Yes 24 kg (8 kg)
3 Yes Alive & well II Yes No 23 kg (19 kg)
4 Yes Alive & well I Yes Yes 47 kg (44 kg)
5 Yes Alive & well I Yes Yes 32 kg (14 kg)
6 Yes Alive & well I Yes Yes 53 kg (37 kg)
7 Yes Alive & well II Yes No 54 kg (47 kg)
8 N/A dead N/A N/A N/A N/A
9 Yes Alive & well I Yes Yes 29 kg (14 kg)
10 N/A dead N/A N/A N/A N/A
11 Yes Alive & well I Yes Yes 24 kg (11 kg)
12 Yes dead N/A N/A N/A N/A
13 Yes Alive & well I Yes Yes 21 kg (10 kg)
14 Yes Alive & well II Yes No 22 kg (9 kg)
15 Yes Alive & well I Yes Yes 24 kg (11 kg)
16 Yes Alive & well I Yes Yes 19 kg (9 kg)
17 Yes Alive & well I Yes Yes 55 kg (52 kg)
18 Yes Alive & well I Yes Yes 20 kg (9 kg)
19 Yes Alive & well I Yes Yes 54 kg (26 kg)
20 Yes Alive & well I Yes Yes 22 kg (11 kg)
21 Yes Alive & well I Yes Yes 15 kg (11 kg)
22 Yes Alive & well I Yes Yes 22 kg (13 kg)
23 No N/A N/A N/A N/A N/A
24 Yes Alive & well I Yes Yes 43 kg (26 kg)
25 No Dead N/A N/A N/A N/A
TEVG, Tissue-engineered vascular graft; NYHA, New York Heart Association; N/A, not available.
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SUnited States Food and Drug Administration and our insti-
tutional review board for permission to implant TEVGs in
humans with single ventricle physiology.
In conclusion, this trial demonstrates the feasibility of us-
ing tissue-engineering technology to create vascular grafts
for use as extracardiac TCPCs. Inasmuch as stenosis is the pri-
mary mode of graft failure on TEVGs, further follow-up and
investigation for the mechanism of stenosis are warranted.
Continued study regarding themechanisms of TEVG stenosis
will allow us to generate the next generation of TEVGs.References
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Dr John Edmund Mayer, Jr (Boston, Mass). You have some
patients who have not survived long term in your tissue-engineered
extracardiac Fontan group. Do you have any histologic studies on
those explanted grafts from autopsy?
Dr Hibino. Unfortunately, for these TCPC graft-implanted pa-
tients, the families declined autopsies; therefore, we do not have
the histologic information. We have the histologic data, however,
from reoperation patients. In these patients we used a tissue engi-
neered graft as a patch for pulmonary angioplasty in a stenosed
region. After the angioplasty, pulmonary artery stenosis developed
again, including the portion replaced with the TEVG. Here is the
histology of the explanted graft at reoperation. In this image we
note endothelialization of the tissue and smooth muscle layer for-
mation, which suggests neotissue formation.ery c February 2010
FIGURE E1. Three-dimensional CT 1 year after TEVG implantation. The
graft is patent and there is no aneurysmal dilation. Arrows denote extracar-
diac TCPC graft.
FIGURE E2. Partial mural thrombus 1 year after TEVG implantation (A, arrows) was successfully treated with warfarin anticoagulation (B, arrows).
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TABLE E1. Patient demographics, diagnoses, and graft type at the time of implantation
Patient Age (y) Weight (kg) Gender TEVG (PGA/PLA) Size (mm) Diagnosis
1 2 11 M PLA 16 Asplenia, AVSD (A), small RV
2 1 7 M PLA 20 Asplenia, SRV, DORV, TAPVC (Ibþ III)
3 7 18 F PLA 18 Concordant criss-cross heart, DORV, PAA, MS
4 21 44 F PLA 24 TA (Ib)
5 4 14 M PLA 20 SRV, DORV, AVVA
6 12 36 F PLA 24 Total sinus defect, ASD, TR (III)
7 17 46 M PLA 24 Aspenia, SLV, CAVVR (III)
8 19 47 F PLA 22 TA (Ib)
9 3 13 F PLA 12 Polyspenia, SRV
10 2 7 F PLA 16 HLHS, MA, IAA (A)
11 2 11 F PGA 16 Asplenia, SRV, PAA, nonconfluent PA
12 13 23 F PLA 20 PPA, ASD (II), sinusoidal communication
13 2 9 M PGA 16 SLV, DILV, Lt AVVA
14 2 9 F PGA 18 DORV, small LV, VSD, PS, ASD (II)
15 2 11 F PGA 12 Polysplenia, cAVSD (A), DORV, PS, CAVVR
16 2 8 F PGA 16 Asplenia, SRV, CAVV, CA, TAPVC (Ib), CAVVR (I)
17 24 51 M PGA 18 TA (Ia), RA giant thrombosis
18 1 8 M PGA 16 SRV, DIRV, PA, ASD (II)
19 11 25 M PGA 18 Asplenia, cAVSD, PS, CAVV, CAVVR (I)
20 2 11 F PGA 12 Polysplenia, cAVSD, PS, CAVV, CAVVR (I)
21 3 10 F PGA 16 DORV, VSD, small RA, PLSVC, TAPVC (IIb)
22 4 13 M PGA 18 PPA, ASD (II), PDA, sinusoidal communication
23 4 14 F PGA 18 SLV, DILV, PAA, ASD, bilateral SVC
24 13 25 F PGA 16 Asplenia, SRV
25 2 9 M PGA 18 TA, SAS
TEVG, Tissue-engineered vascular graft; PGA, Polyglycolic acid; PLA, poly-L-lactic acid; AVSD, atrioventricular septal defect; RV, right ventricle; SRV, single right ventricle;
DORV, double-outlet right ventricle; TAPVC, total anomalous pulmonary venous connection; PAA, pulmonary artery atresia; MS, mitral stenosis; TA, tricuspid atresia; AVVA,
atrioventricular valve atresia; ASD, atrial septal defect; TR, tricuspid regurgitation; SLV, single left ventricle; CAVVR, common atrioventricular valve regurgitation; SRV, single
right ventricle; HLHS, hypoplastic left heart syndrome;MA,mitral atresia; IAA, interruption of aortic arch; PA, pulmonary artery; PPA, pure pulmonary atresia; DILV, double-inlet
left ventricle; LV, left ventricle; VSD, ventricular septal defect; PS, pulmonary stenosis; ASD, atrial septal defect; cAVSD, complete atrioventricular septal defect; CAVV, common
atrioventricular valve; CA, common atrium; RA, right atrium; PLSVC, persistent left superior vena cava; PDA, patent ductus arteriosus; SVC, superior vena cava; SAS, subaortic
stenosis.
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